Novogen's Dr James Garner explores the company's transformation

Photo credit: Phalinn Ooi

The Australian biotech Novogen Ltd (ASX: NRT) has undergone a massive transformation over the past 12 months under the leadership of its new CEO, Dr James Garner.

The former head of Sanofi's Research and Development team in Singapore, Dr Garner has very intentionally shifted Novogen's focus, business model and team. So much so that the company has in-licensed a new drug from Genentech (part of pharmaceutical giant, Roche) to develop a promising new treatment for the most aggressive form of brain cancer, called Glioblastoma Multiforme.

Oncologists around the world now watch on as Novogen prepares to begin a Phase II trial of the drug, GDC-0084.

Swings & Roundabouts speaks with Dr Garner as he reaches 12 months in the role about the company's exciting pipeline and the potential for GDC-0084.

Listen to the broadcast

Key topics covered include:

  • Dr Garner's three-pronged approach to transforming the company over the past 12 months

  • Why the company has shifted in focus from early stage research to clinical development and Phase I and II human trials

  • How Novogen was able to win the trust and confidence of Genentech to partner on the development of GDC-0084

  • Why GDC-0084 is one of the most exciting drugs in development for Glioblastoma sufferers

"I've spent most of my working life in pharmaceutical companies and I've seen some very successful work in those companies," Dr Garner told host Will Canty.  

"I've also seen things I've felt could be done better in a smaller, more agile, more nimble company. So part of what's excited me about coming to Novogen is the opportunity to do that."

About Swings and Roundabouts
Launched in 2016, Swings and Roundabouts is an internet channel which features short interviews with analysts, brokers, fund managers, entrepreneurs, philanthropists and general raconteurs. 
Tune in regularly via Boardroom.Media
For more information or to suggest an interview topic, please contact:
Jane Lowe, IR Department, via: or
Will Canty, Boardroom.Media, via:
Listeners should note that the info discussed is general in nature and does not constitute financial advice.  It does not take into consideration any specific needs, situations or objectives. Before making any financial decisions you should make sure you are comfortable that the strategy suits your needs and objectives, and your risk profile. If necessary, you should seek professional advice.bout Swings and Roundabouts